Literature DB >> 10672322

alpha-Synuclein is expressed in a variety of brain tumors showing neuronal differentiation.

M Kawashima1, S O Suzuki, K Doh-ura, T Iwaki.   

Abstract

alpha-Synuclein is presynaptic nerve terminal protein and its immunoreactivity has been observed in such neurodegenerative structures as senile plaques of Alzheimer's disease or Lewy bodies of Parkinson's disease. The physiological role of alpha-synuclein is still unknown. It is speculated that alpha-synuclein may be expressed in brain tumors, especially in those showing neuronal differentiation. We examined the immunohistochemical localization of alpha-synuclein in 77 human brain tumors. alpha-Synuclein was widely distributed in the brain tumors showing neuronal differentiation. As a result, positive immunostaining for alpha-synuclein was observed in ganglioglioma, medulloblastoma, neuroblastoma, primitive neuroectodermal tumor, pineocytoma/pineoblastoma, and central neurocytoma. Compared with other neuronal markers, the positive ratio of alpha-synuclein was not as high as synaptophysin, microtubule-associated protein 2, neuron-specific enolase and tau, but it was higher than neurofilament and chromogranin A. The expression of synaptophysin was diffusely observed in the cytoplasm, cellular processes and nucleus in tumors showing neuronal differentiation; however, the expression of alpha-synuclein was predominantly observed in the cytoplasm of the tumors as well as in the cellular processes. On the other hand, non-neuronal brain tumors such as astrocytic tumors or meningiomas were totally negative for alpha-synuclein. In conclusion, the appearance of an alpha-synuclein-positive structure was not limited to neurodegenerative diseases, but could also be detected in neoplastic cells showing neuronal differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10672322     DOI: 10.1007/pl00007419

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  23 in total

Review 1.  Neurocytoma: a comprehensive review.

Authors:  Mehar Chand Sharma; Prabal Deb; Suash Sharma; Chitra Sarkar
Journal:  Neurosurg Rev       Date:  2006-08-29       Impact factor: 3.042

2.  Identification of genes regulated by the EWS/NR4A3 fusion protein in extraskeletal myxoid chondrosarcoma.

Authors:  Christine Filion; Yves Labelle
Journal:  Tumour Biol       Date:  2012-05-18

3.  Clinical course of central neurocytoma with malignant transformation-an indication for craniospinal irradiation.

Authors:  Petra Mozes; Erika Szanto; Laszlo Tiszlavicz; Pal Barzo; Adrienne Cserhati; Emese Fodor; Katalin Hideghety
Journal:  Pathol Oncol Res       Date:  2013-10-12       Impact factor: 3.201

4.  CRABP-II methylation: a critical determinant of retinoic acid resistance of medulloblastoma cells.

Authors:  Yuan-Shan Fu; Qian Wang; Jing-Xin Ma; Xiang-Hong Yang; Mo-Li Wu; Kai-Li Zhang; Qing-You Kong; Xiao-Yan Chen; Yuan Sun; Nan-Nan Chen; Xiao-Hong Shu; Hong Li; Jia Liu
Journal:  Mol Oncol       Date:  2011-11-25       Impact factor: 6.603

5.  Central neurocytoma: two case reports and review of the literature.

Authors:  Antonio De Tommasi; Pietro Ivo D'Urso; Claudio De Tommasi; Francesca Sanguedolce; Antonia Cimmino; Pasqualino Ciappetta
Journal:  Neurosurg Rev       Date:  2006-09-05       Impact factor: 3.042

6.  C-terminal part of α-synuclein mediates its activity in promoting proliferation of dopaminergic cells.

Authors:  Juanjuan Yin; Junyan Han; Chen Zhang; Qiu-Lan Ma; Xin Li; Furong Cheng; Guangwei Liu; Yaohua Li; Kenji Uéda; Piu Chan; Shun Yu
Journal:  J Neural Transm (Vienna)       Date:  2011-02-18       Impact factor: 3.575

Review 7.  Molecular genetics of pineal region neoplasms.

Authors:  M D Taylor; T G Mainprize; J A Squire; J T Rutka
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

Review 8.  Parkinson's disease and cancer: two wars, one front.

Authors:  Michael J Devine; Hélène Plun-Favreau; Nicholas W Wood
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

9.  α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease.

Authors:  Eitan Israeli; Eugenia Yakunin; Yonaton Zarbiv; Amir Hacohen-Solovich; Haya Kisos; Virginie Loeb; Michal Lichtenstein; Tziona Ben-Gedalya; Ofra Sabag; Eli Pikarsky; Haya Lorberboum-Galski; Ronit Sharon
Journal:  PLoS One       Date:  2011-05-18       Impact factor: 3.240

10.  Adeno-associated virus-delivered alpha synuclein inhibits bladder cancer growth via the p53/p21 signaling pathway.

Authors:  Zhengcun Wu; Chengxing Xia; Chao Zhang; Donghong Tang; Feineng Liu; Yitian Ou; Jiahong Gao; Hongkun Yi; Delin Yang; Kaili Ma
Journal:  Cancer Gene Ther       Date:  2022-01-21       Impact factor: 5.854

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.